Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;6(3):835-838.
doi: 10.1016/j.ekir.2020.11.025. Epub 2020 Nov 27.

Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m2 or on Renal Replacement Therapy

Christopher Estiverne  1 , Ian A Strohbehn  2 , Zain Mithani  3 , Jamie S Hirsch  4 , Rimda Wanchoo  4 , Pranisha Gautam Goyal  5 , Scott Lee Dryden-Peterson  1 , Jeffrey C Pearson  1 , David W Kubiak  1 , Alyssa R Letourneau  2 , Roby Bhattacharyya  2 , Kenar D Jhaveri  4 , Meghan E Sise  2
Affiliations

Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m2 or on Renal Replacement Therapy

Christopher Estiverne et al. Kidney Int Rep. 2021 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Alanine aminotransferase (ALT) and serum creatinine trends during and after remdesivir. (a) ALT values for all 18 patients. Serum creatinine trends for the 13 patients not requiring renal replacement therapy (RRT) before starting remdesivir are shown in Figure 1b. Patients with end-stage kidney disease (2) or acute kidney injury on RRT (3) at the time of starting remdesivir are not shown in Figure 1b. Patients who initiated remdesivir in the intensive care unit (ICU) are shown in blue. Non-ICU patients (yellow) were receiving care on a medical floor or step-down unit. ALT and creatinine values recorded while on remdesivir treatment are shown with solid lines, and the following 7 days are shown with dashed lines. The date of death is shown with a red X, and hospital discharge is annotated by a solid circle. One patient died while taking remdesivir due to cardiac arrest and shock that was not attributed to remdesivir by the site investigator.
See this image and copyright information in PMC

References

    1. Beigel J.H., Tomashek K.M., Dodd L.E. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020;383:994. - PubMed
    1. Spinner C.D., Gottlieb R.L., Criner G.J. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–1057. - PMC - PubMed
    1. Adamsick M.L., Gandhi R.G., Bidell M.R. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020;31:1384–1386. - PMC - PubMed
    1. Hirsch J.S., Ng J.H., Ross D.W. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209–218. - PMC - PubMed
    1. Gupta S., Hayek S.S., Wang W. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1–12. - PMC - PubMed

LinkOut - more resources